Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 10, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in interests in Ordinary Share American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific transaction rather than a financial performance report.
Material Changes
The filing details a specific transaction involving Mrs. P. Phelan, who acquired a beneficial interest in 0.2108 Ordinary Share ADRs. This acquisition resulted from the reinvestment of a dividend paid to Ordinary Share ADR holders on January 5, 2006, through the US Global BuyDirect Plan administered by The Bank of New York. The purchase price was $52.4640 per ADR.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly limited to the notification of the director's transaction in accordance with Disclosure Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Type: Dividend reinvestment via the US Global BuyDirect Plan.
- Individual Involved: Mrs. P. Phelan.
- Shares Acquired: 0.2108 Ordinary Share ADRs.
- Price per ADR: $52.4640.
- Dividend Payment Date: January 5, 2006.
- Notification Date: January 10, 2006.